Wei Wu He's insider trading at CASI Pharmaceuticals
SEC Form 4 filings for He Wei-Wu,

Insider trading of Wei Wu He, a Director at CASI CASI Pharmaceuticals, Inc.

Most recently Wei Wu He bought 100,000 shares worth $195,000.00 on 10 October 2017.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-10-10 Wei Wu He
Director
Director Buy 100,000 $1.95 $195,000.00
2017-10-10
847,527 SEC insider form 4
2017-10-05 Wei Wu He
Director
Director Buy 200,000 $1.83 $366,000.00
2017-10-05
747,527 SEC insider form 4
2017-09-18 Wei Wu He
Director
Director Buy 207,502 $1.75 $363,128.50
2017-09-18
547,527 SEC insider form 4
2017-09-14 Wei Wu He
Director
Director Buy 315,327 $1.33 $419,384.91
2017-09-14
340,025 SEC insider form 4
2016-10-03 Wei Wu He
Director
Director Buy 1,871,605 $1.19 $2,227,209.95
2016-10-03
1,871,605 SEC insider form 4
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

  • CASI Pharmaceuticals, Inc., 9620 Medical Center Drive, Rockville 20850, United States
  • casipharmaceuticals.com
  • 240-864-2600
Messenger